NASACORT HFA
LOE ApproachingNDANASALSPRAY, METERED
Approved
Apr 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NASACORT HFA is a nasal spray metered-dose inhaler containing triamcinolone acetonide, a corticosteroid approved in 2004. It is indicated for allergic rhinitis and other nasal inflammatory conditions. The drug works by reducing inflammatory mediators in nasal tissue, providing symptomatic relief of nasal congestion, sneezing, and itching.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%), suggesting smaller team size and focus on defensive positioning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Career opportunities on NASACORT HFA are limited given zero linked job postings and LOE-approaching lifecycle stage. Positions available are primarily defensive and focused on maximizing existing market presence, managing competitive erosion, and preparing for generic transition.
Brand ManagerField Sales Representative
Worked on NASACORT HFA at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.